We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Pr-conceptional Progesterone for Unexplained Recurrent Miscarriage

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: August 22, 2012
Last Update Posted: April 5, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
alaa eldeen mahmoud ismail, Woman's Health University Hospital, Egypt
In women with unexplained recurrent miscarriages, progesterone (400 mg pessaries, twice daily), started soon as possible at luteal phase and after a positive pregnancy test and continued to 28 weeks of gestation, compared to placebo, ).

Condition Intervention Phase
Abortion, Habitual Drug: Progesterone Other: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by alaa eldeen mahmoud ismail, Woman's Health University Hospital, Egypt:

Primary Outcome Measures:
  • Number of patients continued the pregnancy beyond 20 weeks gestation. [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Number of miscarriages [ Time Frame: 2 years ]

Other Outcome Measures:
  • Number of Live Birth [ Time Frame: 2 years ]
  • Number of preterm delivery [ Time Frame: 2 years ]

Enrollment: 700
Study Start Date: September 2012
Study Completion Date: November 2015
Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Progesterone group
progesterone (400 mg pessary, once daily)
Drug: Progesterone
Placebo Comparator: Placebo group
Placebo (pessary, once daily)
Other: Placebo

Detailed Description:

Progesterone improves secondary outcomes such as gestation at delivery, on-going pregnancy at 12 weeks, survival at 28 days of neonatal life.

. Progesterone, compared to placebo, does not incur substantial adverse effects to the mother or the neonate.

Explore differential or subgroup effects of progesterone in prognostic subgroups.

. Perform an economic evaluation for cost-effectiveness.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Women with unexplained recurrent miscarriages (2 or more consecutive first trimester miscarriages).
  2. Age 18-39 years at randomisation (likelihood of miscarriages due to chromosomal aberrations is higher in older women; such miscarriages are unlikely to be prevented by progesterone therapy).
  3. Spontaneous conception (as confirmed by urinary pregnancy tests).
  4. Willing and able to give informed consent.

Exclusion Criteria:

  1. Age less than twenty or above forty years old.
  2. Antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies [IgG or IgM]); other recognised thrombophilic conditions (testing according to usual clinic practice)
  3. Intrauterine abnormalities (as assessed by ultrasound, hysterosonography, hysterosalpingogram, or hysteroscopy).
  4. Fibroids distorting uterine cavity.
  5. Abnormal parental karyotype.
  6. Other identifiable causes of recurrent miscarriages (tests initiated only if clinically indicated) e.g., diabetes, thyroid disease and systemic lupus erythematosus (SLE).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01670929

Women's Health Hospital
Assiut, Egypt
Sponsors and Collaborators
Woman's Health University Hospital, Egypt
Principal Investigator: Alaa M Ismail, M D Faculity of medicine,Assiut university
  More Information

Responsible Party: alaa eldeen mahmoud ismail, M D, Woman's Health University Hospital, Egypt
ClinicalTrials.gov Identifier: NCT01670929     History of Changes
Other Study ID Numbers: PPROURM
First Submitted: August 17, 2012
First Posted: August 22, 2012
Last Update Posted: April 5, 2016
Last Verified: April 2016

Keywords provided by alaa eldeen mahmoud ismail, Woman's Health University Hospital, Egypt:
recurrent miscarriages

Additional relevant MeSH terms:
Abortion, Habitual
Abortion, Spontaneous
Pregnancy Complications
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs